Core Insights - Solventum (SOLV) reported Q4 2025 adjusted EPS of $1.57, exceeding the Zacks Consensus Estimate of $1.50 by 4.7%, and showing an 11.3% year-over-year improvement [1] - The company achieved revenues of $1.99 billion, a 3.7% increase from the previous year, and beat the Zacks Consensus Estimate by 1.6% [2] Revenue Details - Revenue growth was driven by all segments, particularly the Infection Prevention and Surgical Solutions business within MedSurg and Dental Solutions [2] - Organic sales growth was reported at 3.5%, with shares down 2.5% in after-hours trading on Feb. 26 [2] Segmental Performance - **MedSurg**: Revenues reached $1.24 billion, up 5.2% reportedly and 3.2% organically year-over-year, driven by NPWT and V.A.C. Peel and Place Dressings [3] - **Dental Solutions**: Revenues totaled $343 million, an 8.6% increase year-over-year, supported by strong performance in core restoratives and recent product launches [4] - **Health Information Systems (HIS)**: Revenues amounted to $348 million, up 3.7% reportedly and 3.2% organically, driven by the adoption of 360 Encompass revenue cycle management [4] Margins and Expenses - Adjusted gross profit was $1.07 billion, down 8.3% year-over-year, with an adjusted gross margin of 53.5%, a decrease of approximately 270 bps [5] - Selling, general and administrative expenses were $759 million, down 3.2% year-over-year, while research and development expenses totaled $175 million, down 12.1% [5] Financial Position - Solventum ended Q4 with cash, cash equivalents, and investments of $8.78 million, a decrease from $1.64 billion in the previous quarter [8] - Total assets increased to $14.29 billion from $13.97 billion in the previous quarter [8] 2026 Guidance - The company expects organic sales growth at the higher end of 2-3%, with adjusted EPS projected between $6.40 and $6.60 [9] - The Zacks Consensus Estimate for earnings is $6.36 per share [9] Strategic Initiatives - Solventum completed its acquisition of Acera Surgical, expanding its MedSurg portfolio, and launched a "Transform for the Future" initiative aimed at delivering approximately $500 million in annual cost savings [11] - Progress on separation from 3M is ahead of plan, with improvements in service levels and operational control [12]

Core Insights - Solventum (SOLV) reported Q3 2025 adjusted EPS of $1.50, exceeding the Zacks Consensus Estimate of $1.43 by 4.9%, but down 8.5% year over year [1][7] - Revenues reached $2.1 billion, a 0.7% increase from the previous year, with organic sales growth of 2.7%, driven by strong performance in Dental Solutions and Health Information Systems [2][7] - The company raised its 2025 EPS outlook to $5.98-$6.08, anticipating organic sales growth at the higher end of 2-3% [12][7] Revenue Details - Total revenues were $2.1 billion, up 0.7% year over year, and beat the Zacks Consensus Estimate by 0.3% [2] - Organic sales growth was primarily driven by strong performance in Dental Solutions and Health Information Systems [2] Segmental Performance - **MedSurg**: Revenues totaled $1.21 billion, up 2.1% reportedly and 1.1% organically year over year, driven by NPWT growth and new product launches [4] - **Dental Solutions**: Revenues reached $340 million, an 8.4% increase year over year, driven by core restoratives and fluoride treatment adoption [5] - **Health Information Systems**: Revenues amounted to $345 million, up 5.9% reportedly and 5.6% organically, supported by revenue cycle management adoption [8] - **Purification and Filtration**: Revenues were $128 million, down 28.7% year over year, reflecting the divestment of this segment [8] Margin Analysis - Adjusted gross profit was $1.17 billion, down 1.9% year over year, with an adjusted gross margin of 55.8%, down approximately 150 bps [9] - Adjusted operating income totaled $431 million, down 9.3% year over year, with an adjusted operating margin of 20.6%, down approximately 220 bps [10] Financial Position - Solventum ended Q3 with cash and investments of $1.64 billion, a significant increase from $492 million in the previous quarter [11] - Total assets decreased to $13.97 billion from $15.07 billion in the previous quarter [11] - Cumulative net cash from operating activities was $274 million, down from $966 million in the year-ago period [11] 2025 Guidance - The company raised its sales guidance for 2025, expecting organic sales growth at the higher end of 2-3% [12] - Adjusted EPS is now projected to be in the range of $5.98-$6.08, up from the previous estimate of $5.88-$6.03 [12] Strategic Initiatives - Solventum is focused on operational discipline, supply-chain optimization, and cost-saving initiatives to offset inflationary pressures [14] - Progress on separation from 3M is ahead of schedule, enhancing operational control and service levels [15] - The successful divestment of the Purification and Filtration business has strengthened the balance sheet and provided flexibility for future growth [14]